Successful Treatment of Chronic Pseudophakic Macular Edema (Irvine-Gass Syndrome) with Interferon Alpha: A Report of Three Cases

Purpose: To describe treatment of chronic Irvine-Gass syndrome (CME) with interferon (IFN) alpha. Methods: Interventional retrospective case series. IFN alpha-2a was administered at a dose of 3 million IU/day subcutaneously for 4 weeks, and was tapered thereafter. Treatment efficacy was assessed by...

Full description

Saved in:
Bibliographic Details
Published in:Ocular immunology and inflammation 2011-06, Vol.19 (3), p.216-218
Main Authors: Deuter, Christoph M. E., Gelisken, Faik, Stübiger, Nicole, Zierhut, Manfred, Doycheva, Deshka
Format: Article
Language:English
Subjects:
Aged
Chronic Disease
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Injections, Subcutaneous
Interferon-alpha - administration & dosage
Macular Edema - drug therapy
Male
Pseudophakia
Recombinant Proteins
Retrospective Studies
Tomography, Optical Coherence
Treatment Outcome
Visual Acuity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: To describe treatment of chronic Irvine-Gass syndrome (CME) with interferon (IFN) alpha. Methods: Interventional retrospective case series. IFN alpha-2a was administered at a dose of 3 million IU/day subcutaneously for 4 weeks, and was tapered thereafter. Treatment efficacy was assessed by best-corrected visual acuity (BCVA) and by optical coherence tomography (OCT). Results: Three patients (4 eyes) with chronic Irvine-Gass syndrome were treated. Ineffective pretreatment included local and systemic corticosteroids. Within 4 weeks, IFN alpha led to resolution of CME in all eyes. BCVA improved in 3 eyes and remained unchanged in 1 eye. During follow-up of 3-11 months no relapse of CME occurred. No systemic or local side effects were noted. Conclusions: IFN alpha has been demonstrated to be a successful and well-tolerated treatment option for resistant chronic pseudophakic CME. Further studies are necessary to evaluate the role of IFN alpha in Irvine-Gass syndrome.
ISSN:0927-3948
1744-5078
DOI:10.3109/09273948.2011.562341